Exploring industry stakeholder perspectives on a clinical testbed for evaluating the handling of protein drugs in hospitalsShow others and affiliations
2025 (English)In: Journal of Pharmaceutical Sciences, ISSN 0022-3549, E-ISSN 1520-6017, Vol. 114, no 4, article id 103704Article in journal (Refereed) Published
Abstract [en]
Protein drugs, such as therapeutic antibodies, are complex and require careful handling to maintain their efficacy and quality. Stress factors in hospitals, like temperature variations and mechanical shocks during transport, may negatively impact the stability of protein drugs (e.g. various monoclonal antibodies). The pharmaceutical industry possesses extensive knowledge about their product formulations but often the transfer of knowledge from lab studies into in-hospital handling procedures is challenging. To address this gap and find a way to bridge academia, healthcare, and industry, seven semi-structured interviews were conducted with experts from pharmaceutical companies across five countries. This study aimed to explore the opinions of formulation experts regarding stress evaluation in clinical settings. Thematic analysis of the interviews revealed four key themes: The human factor in clinical sites, clinical sites as data providers, potential complexities in conducting tests within a clinical setting, and challenges associated with product-specific methods, equipment and devices. This study also suggests tools for setting up clinical test beds that can help the pharmaceutical industry improve stress evaluation and understand clinical product handling. Direct collaboration with clinical sites is crucial, as experts perceive improved evaluation methods and education to be necessary for ensuring safe medicines for patients.
Place, publisher, year, edition, pages
Elsevier B.V. , 2025. Vol. 114, no 4, article id 103704
Keywords [en]
Antibodies, Monoclonal; Drug Industry; Drug Stability; Hospitals; Humans; Proteins; monoclonal antibody; monoclonal antibody; protein; Article; clinical testbed; decision making; drug industry; health care industry; health care personnel; hospital; human; industry stakeholder perspective; interview; pharmacist; protein aggregation; questionnaire; semi structured interview; stakeholder participation; temperature; thematic analysis; work environment; chemistry; drug industry; drug stability; hospital; procedures
National Category
Basic Medicine
Identifiers
URN: urn:nbn:se:ri:diva-78314DOI: 10.1016/j.xphs.2025.103704Scopus ID: 2-s2.0-85219115413OAI: oai:DiVA.org:ri-78314DiVA, id: diva2:2000153
Note
This work has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (RealHOPE grant n°101007939).
2025-09-232025-09-232025-09-23Bibliographically approved